Article Text

Download PDFPDF

30 Utilization of and barriers to individual treatment trials in mucopolysaccharidosis – interim results of an expert survey
Free
  1. Anna-Maria Wiesinger1,
  2. Florian Lagler1,
  3. Maurizio Scarpa2,
  4. Roberto Giugliani3,
  5. Christina Lampe4,
  6. Christoph Kampmann5
  1. 1Institute of Congenital Metabolic Diseases, Paracelsus Medical University Salzburg
  2. 2Regional Coordinating Center of Rare Diseases, University of Udine
  3. 3Department of Genetics, University of Rio Grande de Sul
  4. 4Department of Child and Adolescent Medicine, Unviersity Hospital Giessen Marburg
  5. 5Department of Pediatric Cardiology, University Hospital Mainz

Abstract

Introduction Mucopolysaccharidoses (MPS), comprise a group of rare chronically debilitating metabolic diseases and associated with reduced life expectancy and a substantial unmet clinical need. Current research directs towards a number of new treatment targets and strategies. Individual treatment trials (ITT) could make these options rapidly available to patients. Based on scientific publication, this is hardly used. We assess the utilization of and relevant barriers to ITT in MPS as well as potential solutions.

Methods Phase 1 was done with 5 international top experts. After this interim analysis, the survey will be rolled out to a broader group of experts.

Results Five MPS experts from Austria, Brazil, Germany and Italy have been enrolled. In total these clinicians manage about 350 MPS patients. Only three experts ever ran 1–3 numbers of ITT in MPS patients, solely MPS type II (n=2) and VI (n=1), summing up to a total of five ITTs, which is about 1.4% of their patients. The treatments used in ITTs comprise Montelukast, THC, Curcuma and a viral vector with transgene. As barriers for a wider use of ITTs, the im-practicability for implementation (n=1) and the insufficient training in ITT (n=1) have been indicated. All experts consider it highly likely that a decision analysis tool increases the use of ITT in MPS.

Conclusions ITT are used in about 1% of MPS patients. This seems extremely low, considering the commonness of off label use in children with severe conditions, the high unmet medical need in MPS and the number of research results, which indicate various promising repurposing strategies. This interim analysis already demonstrates several relevant barriers and high potential of the planned decision framework tool to overcome this.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.